Prognia
Drug Database
🇪🇺EU · EMARefusedATC: N07XXOrphan Medicine

Albrioza(sodium phenylbutyrate;ursodoxicoltaurine)

Amyotrophic Lateral Sclerosis

Marketing Authorisation Holder: Amylyx Pharmaceuticals EMEA B.V.

INN: sodium phenylbutyrate;ursodoxicoltaurine

Indication

Treatment of amyotrophic lateral sclerosis (ALS)

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Albrioza — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.